恶性肿瘤患者的脓毒症与脓毒性休克:GRRR-OH 研究
该研究基于Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique数据库(1994-2015),纳入7个欧洲ICU中因脓毒症或脓毒性休克入院的恶性肿瘤患者2062例,其中血液系统恶性肿瘤1700例(82.4%)、实体瘤362例(17.6%),31.0%入ICU时中性粒细胞减少。30天死亡率为39.9%(823例死亡)。校正年份和来源数据集后,入ICU年份与30天死亡率显著下降相关(OR 0.96,95%CI 0.93-0.98,p=0.001);机械通气(OR 3.25,95%CI 2.52-4.19)和血管升压药使用(OR 1.42,95%CI 1.10-1.83)与30天死亡率独立相关,而基础恶性肿瘤类型、异基因造血干细胞移植和中性粒细胞减少与30天死亡率无独立关联。作者认为,随着预后改善,临床医生应考虑更新此类患者的收治政策和治疗目标。
要点
- 2062例恶性肿瘤合并脓毒症/脓毒性休克患者30天死亡率为39.9%(823例死亡)。
- 入ICU年份与30天死亡率显著下降独立相关(OR 0.96,95%CI 0.93-0.98,p=0.001)。
- 机械通气(OR 3.25,95%CI 2.52-4.19)和血管升压药使用(OR 1.42,95%CI 1.10-1.83)与30天死亡率独立相关。
- 基础恶性肿瘤类型、异基因造血干细胞移植和中性粒细胞减少与30天死亡率无独立关联。
- 作者认为,随着预后改善,临床医生应考虑更新收治政策和治疗目标。
适用人群与场景
- 7个欧洲ICU中因脓毒症或脓毒性休克入院的恶性肿瘤患者,数据来自Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique数据库(1994-2015)。
- 共2062例,62%为男性,中位年龄59岁(IQR 48-67岁);实体瘤362例(17.6%),血液系统恶性肿瘤1700例(82.4%),包括急性白血病591例(28.7%)、非霍奇金淋巴瘤461例(22.3%)、骨髓瘤244例(11.8%)。
- 250例(12%)接受异基因造血干细胞移植,640例(31.0%)入ICU时中性粒细胞减少。
研究设计与关键结果
- 研究类型为基于GRRR-OH数据库的多中心队列研究,纳入7个欧洲ICU中因脓毒症或脓毒性休克入院的恶性肿瘤患者2062例,数据跨度1994-2015年。
- 主要终点30天死亡率为39.9%(823例死亡)。
- 采用分层模型(入ICU年份和来源数据集为随机变量)分析,入ICU年份与30天死亡率显著下降相关(OR 0.96,95%CI 0.93-0.98,p=0.001)。
- 机械通气(OR 3.25,95%CI 2.52-4.19,p<0.01)和血管升压药使用(OR 1.42,95%CI 1.10-1.83,p<0.01)与30天死亡率独立相关。
- 基础恶性肿瘤类型、异基因造血干细胞移植和中性粒细胞减少与30天死亡率无独立关联。
证据类型、等级与局限
- 证据类型:基于GRRR-OH数据库的多中心队列研究(7个欧洲ICU,1994-2015年)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随着恶性肿瘤合并脓毒症/脓毒性休克患者预后改善,临床医生应考虑更新收治政策和治疗目标。
- 原文未据此给出其他推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Cancer affects up to 20% of critically ill patients, and sepsis is one of the leading reasons for ICU admission in this setting. Early signals suggested that survival might be increasing in this population. However, confirmation studies have been lacking. The goal of this study was to assess trends in survival rates over time in cancer patients admitted to the ICU for sepsis or septic shock over the last 2 decades.
DATA SOURCE: Seven European ICUs.
STUDY SELECTION: A hierarchical model taking into account the year of admission and the source dataset as random variables was used to identify risk factors for day 30 mortality.
DATA EXTRACTION: Data from cancer patients admitted to ICUs for sepsis or septic shock were extracted from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique database (1994-2015).
DATA SYNTHESIS: Overall, 2,062 patients (62% men, median [interquartile range] age 59 yr [48-67 yr]) were included in the study. Underlying malignancies were solid tumors (n = 362; 17.6%) or hematologic malignancies (n = 1,700; 82.4%), including acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma (n = 461; 22.3%), and myeloma (n = 244; 11.8%). Two-hundred fifty patients (12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%) were neutropenic at ICU admission. Day 30 mortality was 39.9% (823 deaths). The year of ICU admission was associated with significant decrease in day 30 mortality over time (odds ratio, 0.96; 95% CI, 0.93-0.98; p = 0.001). Mechanical ventilation (odds ratio, 3.25; 95% CI, 2.52-4.19; p < 0.01) and vasopressors use (odds ratio, 1.42; 95% CI, 1.10-1.83; p < 0.01) were independently associated with day 30 mortality, whereas underlying malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not.
CONCLUSIONS: Survival in critically ill oncology and hematology patients with sepsis improved significantly over time. As outcomes improve, clinicians should consider updating admission policies and goals of care in this population.
参考来源
- Lemiale V, Pons S, Mirouse A, et al. Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. Crit Care Med. 2020. PMID: 32317596. doi:10.1097/CCM.0000000000004322
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。